The Apex Times
Above the Noise
Business Wire
BusinessNorthrop Grumman highlights new FORTITUDE gallium nitride chip as backlog conversion narrative returns to focusThe Apex TimesBusinessDeere vs. CNH: Investors are debating whether Deere’s technology premium is paying offThe Apex TimesBusinessOracle vs. Cisco: Dividend-minded investors are weighing payouts differently than price movesThe Apex TimesBusinessPalantir shares jump after Wall Street upgrades and reports of a new sovereign AI partnershipThe Apex TimesBusinessAMD supply constraints become a market talking point, with investors weighing whether limits can translate into pricing powerThe Apex TimesBusinessMAG 7 Voices puts spotlight on divergent AI paths, from desktop agents to custom chipsThe Apex TimesBusinessDelta Air Lines trims its 2026 profit outlook as fuel costs hit record highsThe Apex TimesBusinessU.S. missile spending spotlight hits Boeing and RTX as Ondas reports $270M in new orders, Stocktwits saysThe Apex TimesBusinessStarbucks is redesigning stores to bring back a cozier “coffeehouse” feelThe Apex TimesBusinessOracle shares drop 5.5% as unusual options trading spikes, with heavy interest in October $145 callsThe Apex TimesBusinessOil at $100-plus and a reported $7 billion offer put ConocoPhillips back in the spotlightThe Apex TimesBusinessApple reportedly trims iPhone orders by as much as 20% as it positions a near-$2,000 foldableThe Apex TimesBusinessNorthrop Grumman highlights new FORTITUDE gallium nitride chip as backlog conversion narrative returns to focusThe Apex TimesBusinessDeere vs. CNH: Investors are debating whether Deere’s technology premium is paying offThe Apex TimesBusinessOracle vs. Cisco: Dividend-minded investors are weighing payouts differently than price movesThe Apex TimesBusinessPalantir shares jump after Wall Street upgrades and reports of a new sovereign AI partnershipThe Apex TimesBusinessAMD supply constraints become a market talking point, with investors weighing whether limits can translate into pricing powerThe Apex TimesBusinessMAG 7 Voices puts spotlight on divergent AI paths, from desktop agents to custom chipsThe Apex TimesBusinessDelta Air Lines trims its 2026 profit outlook as fuel costs hit record highsThe Apex TimesBusinessU.S. missile spending spotlight hits Boeing and RTX as Ondas reports $270M in new orders, Stocktwits saysThe Apex TimesBusinessStarbucks is redesigning stores to bring back a cozier “coffeehouse” feelThe Apex TimesBusinessOracle shares drop 5.5% as unusual options trading spikes, with heavy interest in October $145 callsThe Apex TimesBusinessOil at $100-plus and a reported $7 billion offer put ConocoPhillips back in the spotlightThe Apex TimesBusinessApple reportedly trims iPhone orders by as much as 20% as it positions a near-$2,000 foldableThe Apex TimesBusinessNorthrop Grumman highlights new FORTITUDE gallium nitride chip as backlog conversion narrative returns to focusThe Apex TimesBusinessDeere vs. CNH: Investors are debating whether Deere’s technology premium is paying offThe Apex TimesBusinessOracle vs. Cisco: Dividend-minded investors are weighing payouts differently than price movesThe Apex TimesBusinessPalantir shares jump after Wall Street upgrades and reports of a new sovereign AI partnershipThe Apex TimesBusinessAMD supply constraints become a market talking point, with investors weighing whether limits can translate into pricing powerThe Apex TimesBusinessMAG 7 Voices puts spotlight on divergent AI paths, from desktop agents to custom chipsThe Apex TimesBusinessDelta Air Lines trims its 2026 profit outlook as fuel costs hit record highsThe Apex TimesBusinessU.S. missile spending spotlight hits Boeing and RTX as Ondas reports $270M in new orders, Stocktwits saysThe Apex TimesBusinessStarbucks is redesigning stores to bring back a cozier “coffeehouse” feelThe Apex TimesBusinessOracle shares drop 5.5% as unusual options trading spikes, with heavy interest in October $145 callsThe Apex TimesBusinessOil at $100-plus and a reported $7 billion offer put ConocoPhillips back in the spotlightThe Apex TimesBusinessApple reportedly trims iPhone orders by as much as 20% as it positions a near-$2,000 foldableThe Apex TimesBusinessNorthrop Grumman highlights new FORTITUDE gallium nitride chip as backlog conversion narrative returns to focusThe Apex TimesBusinessDeere vs. CNH: Investors are debating whether Deere’s technology premium is paying offThe Apex TimesBusinessOracle vs. Cisco: Dividend-minded investors are weighing payouts differently than price movesThe Apex TimesBusinessPalantir shares jump after Wall Street upgrades and reports of a new sovereign AI partnershipThe Apex TimesBusinessAMD supply constraints become a market talking point, with investors weighing whether limits can translate into pricing powerThe Apex TimesBusinessMAG 7 Voices puts spotlight on divergent AI paths, from desktop agents to custom chipsThe Apex TimesBusinessDelta Air Lines trims its 2026 profit outlook as fuel costs hit record highsThe Apex TimesBusinessU.S. missile spending spotlight hits Boeing and RTX as Ondas reports $270M in new orders, Stocktwits saysThe Apex TimesBusinessStarbucks is redesigning stores to bring back a cozier “coffeehouse” feelThe Apex TimesBusinessOracle shares drop 5.5% as unusual options trading spikes, with heavy interest in October $145 callsThe Apex TimesBusinessOil at $100-plus and a reported $7 billion offer put ConocoPhillips back in the spotlightThe Apex TimesBusinessApple reportedly trims iPhone orders by as much as 20% as it positions a near-$2,000 foldableThe Apex Times
Back to front
Ark Invest’s Cathie Wood trims AMD and other tech holdings, adding more to biotech in its genomics-focused strategies
The Apex Times

THE APEX TIMES

Business/The Apex Times/Oct 10, 2:18 AM EDT

Ark Invest’s Cathie Wood trims AMD and other tech holdings, adding more to biotech in its genomics-focused strategies

In updated disclosures summarized by Yahoo Finance, Ark Invest cut positions including AMD alongside Alphabet and SpaceX-linked exposure, while its ARK Genomic Revolution ETF and related genomics-heavy allocations continued to build stakes in biotech firms such as Cambrex, and newer gene and platform-focused names.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Ark Invest, led by Cathie Wood, appears to be rebalancing parts of its exchange-traded fund lineup by reducing exposure to several high-profile technology holdings while increasing allocations tied to genomics and healthcare, according to a Yahoo Finance report published October 10, 2026.

The trades highlighted in the report include selling shares of AMD, a major semiconductor company that powers a wide range of computing and data center workloads. The sell-side action also reportedly extended to holdings associated with Alphabet and to a position described as SPCX.

At the same time, the report says Ark Invest’s genomics-focused approach continued to add to healthcare and biotech companies. It names Cambrex (CMPS) as one of the companies Ark loaded up on, alongside names tied to gene- and platform-driven biotech activity.

The Yahoo Finance summary also points to additions involving Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP), two companies whose business models are closely linked to CRISPR-based gene editing. In plain terms, gene-editing companies are betting that precise modifications to DNA can address underlying causes of disease, often aiming to move beyond symptom management toward longer-lasting treatments.

Ark’s genomics tilt was further underscored by the mention that its ARK Genomic Revolution ETF continued to buy biotech companies. The ARK Genomic Revolution ETF is designed to track a portfolio of public companies expected to benefit from advances in genomic science, including tools, therapies, diagnostics, and related enabling technologies.

The sector context matters because semiconductor and biotech pricing pressures can move for different reasons. AMD is primarily exposed to technology spending cycles, competition in chips, and demand for computing and AI-related infrastructure. By contrast, many genomics and biotech outcomes depend on clinical trial readouts, regulatory milestones, manufacturing scale-up, and reimbursement pathways. Switching emphasis between these areas can change the risks a portfolio carries, even if overall market conditions remain unchanged.

The report does not provide, in the text reflected here, the sizes of the transactions, the exact trade dates, or whether the changes occurred across one fund or multiple Ark-managed vehicles. It also does not specify whether each sale fully exited a position or merely reduced exposure, nor does it quantify how much Ark increased its stakes in the named healthcare companies.

For investors and market watchers, the notable takeaway is not a forecast but a portfolio emphasis: Ark’s framework appears to be directing more incremental capital toward genomics-linked companies while trimming some widely held technology names. If Ark continues this pattern, the next catalyst to watch would be whether subsequent filings show sustained reductions in tech exposure and continued increases in gene-editing and related biotech holdings as clinical and regulatory timelines progress.

Why It Matters

  • Shifts like these can change a portfolio’s exposure to different drivers, with semiconductors typically tied to technology spending and biotech tied to clinical and regulatory milestones.
  • Adding to gene-editing companies such as NTLA and CRSP indicates continued emphasis on therapeutic platforms rather than purely hardware or broad tech beta.
  • Trimming positions in large, widely followed technology names may also reflect Ark’s view that near-term upside is more concentrated in healthcare innovation than in certain tech segments.
  • For markets, tracking ETF rebalance patterns can offer a real-time proxy for where active managers see relative value across sectors. (This does not indicate guaranteed outcomes.)

Sources

Key Facts

  • A Yahoo Finance report summarized Ark Invest trades made on or before October 10, 2026.
  • Ark Invest, under Cathie Wood, reportedly sold shares of AMD, as well as holdings referenced as SPCX and GOOG.
  • The report says Ark Invest’s genomics-focused allocations continued adding to healthcare and biotech names.
  • Among companies named as beneficiaries of added capital were CMPS, NTLA, and CRSP.
  • The report specifically references the ARK Genomic Revolution ETF continuing to build biotech positions.

Technology Related